Article Text

Download PDFPDF
Carcinoma of the fallopian tube. A clinical and histopathologic review. The Radiumhemmet series
  1. A.-C. HELLSTRÖM*,
  3. B. NILSSON and
  1. *Department of Gynaecological Oncology, Radiumhemmet
  2. Department of Tumor Pathology, Karolinska Hospital and Institute
  3. Unit of Cancer Epidemiology, Karolinska Hospital, Stockholm, Sweden
  1. Address for correspondence: Ann-Cathrin Hell-ström, Department of Gynaecological Oncology, Radiumhemmet, Karolinska Hospital, S-171 76 Stockholm, Sweden.


A histopathologic and clinical review of the Radiumhemmet series of primary fallopian tube carcinoma (PFTC) treated from 1923 to 1991 revealed that 128 cases fulfilled the diagnostic criteria for PFTC. These cases were staged according to the new FIGO staging rules for PFTC. Survival was studied with respect to prognostic factors such as age, stage, histologic subgroups, degree of differentiation and mode of treatment. The mean age at diagnosis was 56 years. Seventy-four per cent were found to be in stage Ia–IIa and 26 % in stage III–IV. Forty-five per cent were nulliparous and 22 % had evidence of previous pelvic inflammatory disease. Treatment modalities changed during the studied period. Thirty-three per cent of patients underwent surgery with total abdominal hysterectomy and bilateral salpingo-oophorectomy while 67 % were incompletely operated. A trend towards improvement in results was noticed—however, it was not statistically significant. Among the 14 prognostic variables tested in the multivariate analysis the first in rank were stage (P = 0.001) and degree of differentiation of the tumors (P = 0.070). Patients receiving chemotherapy had superior survival rates compared with those without chemotherapy (P = 0.0006) and patients with cisplatinum-containing chemotherapy did better than those without cisplatin.

  • cancer
  • fallopian tube
  • pathology
  • prognosis
  • symptoms
  • treatment

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • This study was supported by the Cancer Society in Stockholm.